

You are invited to attend a ZAVZPRET® (zavegepant)
IN-PERSON SPEAKER PROGRAM



MIGRAINE MANAGEMENT: An Approach for Individualized Care Using an Intranasal CGRP Receptor Antagonist

**Migraine is a disruptive neurological disorder associated with high disease burden.
Join us to learn more about available treatments for your adult patients with migraine.**

Program Objectives

- Recognize the opportunity to tailor treatment based on individual patient's needs
- Provide an overview of CGRP receptor antagonists' mechanism of action
- Consider intranasal delivery and how ZAVZPRET could provide relief to patients with migraine
- Review clinical data for ZAVZPRET, the first and only CGRP receptor antagonist nasal spray indicated for the acute treatment of migraine with or without aura in adults

INDICATION

ZAVZPRET (zavegepant) is indicated for the acute treatment of migraine with or without aura in adults.

Limitations of Use: ZAVZPRET is not indicated for the preventive treatment of migraine.

IMPORTANT SAFETY INFORMATION

Contraindications: Hypersensitivity to ZAVZPRET or any of its components.

Warnings and Precautions

Hypersensitivity Reactions: Hypersensitivity reactions, including facial swelling and urticaria, have occurred with ZAVZPRET. If a hypersensitivity reaction occurs, discontinue ZAVZPRET and initiate appropriate therapy.



Presented By:
GINA BURGE, NP
Speaker is paid by Pfizer.



Date and Time
Thursday, October 2, 2025
6:00 PM Central Time



Location
Park Heights Restaurant
335 East Main Street
Tupelo, Mississippi 38804
(662) 842-5665

Continuing medical education credits are not available for this program.

REGISTER NOW!



PLEASE RSVP FOR AN EVENT BY CONTACTING:

Jordan Mccollum: (662) 212-0007, jordan.mccollum@pfizer.com

Kindly provide your full name, degree, specialty, address including state, and email address when registering so that you can be confirmed. Please also provide the Meeting ID# **INT-0086906** when you RSVP.

Because late arrivals may be prohibited from participating in the program, please make every effort to arrive by the designated start time. You are expected to remain for the duration of the program.

CGRP, calcitonin gene-related peptide.

Please see accompanying full Prescribing Information.

Please see additional Important Safety Information for ZAVZPRET on next page.

PLEASE STAPLE USPI HERE

IMPORTANT SAFETY INFORMATION (CONT.)

Warnings and Precautions (CONT.)

Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of CGRP antagonists in the postmarketing setting.

Monitor patients for new-onset hypertension or worsening of pre-existing hypertension and consider whether discontinuation is warranted.

Raynaud's Phenomenon: Development of Raynaud's phenomenon and recurrence or worsening of pre-existing Raynaud's phenomenon have been reported in the postmarketing setting following the use of CGRP antagonists.

If signs or symptoms of Raynaud's phenomenon develop, discontinue ZAVZPRET. Patients should be evaluated by a healthcare provider if symptoms do not resolve. Patients with a history of Raynaud's phenomenon should be monitored for, and informed about the possibility of, worsening or recurrence of signs and symptoms.

Adverse Reactions: Most common adverse reactions (occurring in $\geq 2\%$ of patients treated with ZAVZPRET and greater than placebo) for ZAVZPRET vs placebo were taste disorders including dysgeusia and ageusia (18% vs 4%), nausea (4% vs 1%), nasal discomfort (3% vs 1%), and vomiting (2% vs $<1\%$).

Drug Interactions: Avoid use with drugs that inhibit or induce OATP1B3 or NTCP transporters. Avoid use of intranasal decongestants; if unavoidable, administer intranasal decongestants at least 1 hour after ZAVZPRET administration.

Use in Specific Populations: *Pregnancy:* It is not known if ZAVZPRET can harm an unborn baby. *Lactation:* It is not known whether ZAVZPRET passes into breast milk. *Hepatic Impairment:* Avoid use in patients with severe hepatic impairment. *Renal Impairment:* Avoid use of ZAVZPRET in patients with creatinine clearance (CL_{CR}) less than 30 mL/min.

Please see accompanying full Prescribing Information on last page or stapled to this invitation.

Notice: Pfizer is committed to the appropriate marketing of its products to ensure that interactions with HCPs are professional exchanges designed to benefit patients and enhance the practice of medicine. All Pfizer-sponsored programs are conducted in accordance with PhRMA Code principles to address a bona fide educational need with appropriate attendees in a venue and manner conducive to informational exchange.

State and Federal Employees: State and federal laws and regulations may carry additional restrictions. By attending this event, you confirm that you have obtained any necessary approvals from your employer.

Public Disclosures: Pfizer reports payment and transfer of value data as required by federal and state transparency laws.

State Law Restrictions:

Minnesota: Regardless of where you practice or reside, if you are a Minnesota-licensed practitioner with prescribing privileges, then you may not consume any food or beverage associated with this event.

Vermont: Regardless of where you practice or reside, if you are a Vermont-licensed HCP, you may not consume any food or beverage associated with this event. Additionally, if you are an employee/agent of a Vermont HCP (e.g., PAs, non-prescribing nurses, etc.), regardless of where you practice or reside, you may not consume any food or beverage associated with this event.

Pfizer does not provide or pay for alcohol in connection with any Pfizer-sponsored program.

HCP, healthcare provider; PA, physician assistant.

This promotional program is for US healthcare professionals only.

